Royalty Pharma plc [RPRX] Director makes an insider sale of 232,185 shares worth 9,635,678.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Royalty Pharma plc shares valued at $9,635,678 were sold by Giuliani Mario Germano on Sep 19. At $41.50 per share, Giuliani Mario Germano sold 232,185 shares. The insider’s holdings dropped to 22,657,815 shares worth approximately $922.17 million following the completion of this transaction.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Also, GG 1978 SICAF SIF S.A. – GG St sold 232,185 shares, netting a total of over 9,635,654 in proceeds. Following the sale of shares at $41.50 each, the insider now holds 21,693,985 shares.

Before that, GG 1978 SICAF SIF S.A. – GG St had sold 154,986 shares from its account. In a trade valued at $6,466,279, the 10% Owner traded Royalty Pharma plc shares for $41.72 each. Upon closing the transaction, the insider’s holdings decreased to 154,986 shares, worth approximately $892.4 million.

Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in mid May. As of April 27, 2022, Goldman has initiated its “Buy” rating for RPRX. Earlier on April 14, 2022, JP Morgan upgraded its rating. Their new recommendation was “an Overweight” for RPRX stock which previously was a “a Neutral”.

Analyzing RPRX’s Price Performance

On Wednesday, Royalty Pharma plc [NASDAQ: RPRX] plunged -0.78% to $40.70. The stock’s lowest price that day was $40.66, but it reached a high of $41.56 in the same session. During the last five days, there has been a drop of approximately -4.10%. Over the course of the year, Royalty Pharma plc shares have jumped approximately 2.13%. Shares of the company reached a 52-week high of $44.75 on 04/14/22 and a 52-week low of $36.15 on 02/24/22. A 50-day SMA is recorded $43.00, while a 200-day SMA reached $40.83. Nevertheless, trading volume fell to 1.39 million shares from 3.48 million shares the previous day.

Support And Resistance Levels for Royalty Pharma plc (RPRX)

According to the 24-hour chart, there is a support level at 40.39, which, if violated, would cause prices to drop to 40.07. In the upper region, resistance lies at 41.29. The next price resistance is at 41.87. RSI (Relative Strength Index) is 31.47 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.12, which suggests the price will decrease in the coming days. Percent R is at 98.87%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Royalty Pharma plc subject to short interest?

Stocks of Royalty Pharma plc saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.3 million shares to 13.43 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 13.73 million shares. A decline of -2.23% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.28 of the overall float, the days-to-cover ratio (short ratio) decline to 6.28.

Which companies own the most shares of Royalty Pharma plc (RPRX)?

According to Morgan Stanley Investment Managem filings, the company currently owns 47,273,159 shares, which is about 10.86% of the total RPRX shares outstanding. The investor’s shares have plunged by -4,127,641 from its previous 13-F filing of 51400800.0 shares. With the completion of the buy transaction, Fidelity Management & Research Co’s stake is now worth $1,418,557,525. The Vanguard Group, Inc. acquire a 3.07% interest valued at $1.34 billion while Baillie Gifford & Co. purchased a 16,867,887 stake. A total of -8,134,900 shares of Royalty Pharma plc were bought by Adage Capital Management LP during the quarter, and 575,550 were bought by BlackRock Fund Advisors. In its current portfolio, Viking Global Investors LP holds 12,370,694 shares valued at $517.22 million.

In terms of Royalty Pharma plc share price expectations, FactSet research, analysts set an average price target of $53.64 in the next 12 months, up nearly 29.21% from the previous closing price of $41.02. Analysts anticipate Royalty Pharma plc stock to reach $60.00 by 2022, with the lowest price target being $49.40. In spite of this, 10 analysts ranked Royalty Pharma plc stock as a Buy at the end of 2022. On April 06, 2022, Morgan Stanley assigned a price target of “an Overweight” to the stock and resumed coverage with a $48.


Please enter your comment!
Please enter your name here